Literature DB >> 26200344

Molecular biology: Salvaging the genome.

Sharanya Sivanand1, Kathryn E Wellen1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26200344     DOI： 10.1038/nature14638

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  13 in total

1.  Systematic variation in gene expression patterns in human cancer cell lines.

Authors:  D T Ross; U Scherf; M B Eisen; C M Perou; C Rees; P Spellman; V Iyer; S S Jeffrey; M Van de Rijn; M Waltham; A Pergamenschikov; J C Lee; D Lashkari; D Shalon; T G Myers; J N Weinstein; D Botstein; P O Brown
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

2.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

Review 3.  DNA methylation in mammals.

Authors:  En Li; Yi Zhang
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-05-01       Impact factor: 10.005

Review 4.  Targeting cancer metabolism: a therapeutic window opens.

Authors:  Matthew G Vander Heiden
Journal:  Nat Rev Drug Discov       Date:  2011-08-31       Impact factor: 84.694

5.  Nucleoside monophosphate kinase may be the key enzyme preventing salvage of DNA 5-methylcytosine.

Authors:  J A Vilpo; L M Vilpo
Journal:  Mutat Res       Date:  1993-04       Impact factor: 2.433

6.  Exclusion of exogenous 5-methyl-2'-deoxycytidine from DNA in human leukemic cells. A study with [2(-14)C]- and [methyl-14C]5-methyl-2'-deoxycytidine.

Authors:  A Jekunen; M Puukka; J Vilpo
Journal:  Biochem Pharmacol       Date:  1983-04-01       Impact factor: 5.858

7.  MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.

Authors:  Helge Gad; Tobias Koolmeister; Ann-Sofie Jemth; Saeed Eshtad; Sylvain A Jacques; Cecilia E Ström; Linda M Svensson; Niklas Schultz; Thomas Lundbäck; Berglind Osk Einarsdottir; Aljona Saleh; Camilla Göktürk; Pawel Baranczewski; Richard Svensson; Ronnie P-A Berntsson; Robert Gustafsson; Kia Strömberg; Kumar Sanjiv; Marie-Caroline Jacques-Cordonnier; Matthieu Desroses; Anna-Lena Gustavsson; Roger Olofsson; Fredrik Johansson; Evert J Homan; Olga Loseva; Lars Bräutigam; Lars Johansson; Andreas Höglund; Anna Hagenkort; Therese Pham; Mikael Altun; Fabienne Z Gaugaz; Svante Vikingsson; Bastiaan Evers; Martin Henriksson; Karl S A Vallin; Olov A Wallner; Lars G J Hammarström; Elisee Wiita; Ingrid Almlöf; Christina Kalderén; Hanna Axelsson; Tatjana Djureinovic; Jordi Carreras Puigvert; Maria Häggblad; Fredrik Jeppsson; Ulf Martens; Cecilia Lundin; Bo Lundgren; Ingrid Granelli; Annika Jenmalm Jensen; Per Artursson; Jonas A Nilsson; Pål Stenmark; Martin Scobie; Ulrika Warpman Berglund; Thomas Helleday
Journal:  Nature       Date:  2014-04-02       Impact factor: 49.962

8.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

Authors:  J L Abbruzzese; R Grunewald; E A Weeks; D Gravel; T Adams; B Nowak; S Mineishi; P Tarassoff; W Satterlee; M N Raber
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

9.  CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer.

Authors:  Melania Zauri; Georgina Berridge; Marie-Laëtitia Thézénas; Kathryn M Pugh; Robert Goldin; Benedikt M Kessler; Skirmantas Kriaucionis
Journal:  Nature       Date:  2015-07-22       Impact factor: 49.962

10.  Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.

Authors:  Kilian V M Huber; Eidarus Salah; Branka Radic; Manuela Gridling; Jonathan M Elkins; Alexey Stukalov; Ann-Sofie Jemth; Camilla Göktürk; Kumar Sanjiv; Kia Strömberg; Therese Pham; Ulrika Warpman Berglund; Jacques Colinge; Keiryn L Bennett; Joanna I Loizou; Thomas Helleday; Stefan Knapp; Giulio Superti-Furga
Journal:  Nature       Date:  2014-04-02       Impact factor: 49.962
View more
  2 in total

1.  Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR).

Authors:  Yanyun Gao; Philipp Zens; Min Su; Camila Anna Gemperli; Haitang Yang; Haibin Deng; Zhang Yang; Duo Xu; Sean R R Hall; Sabina Berezowska; Patrick Dorn; Ren-Wang Peng; Ralph Alexander Schmid; Wenxiang Wang; Thomas Michael Marti
Journal:  J Exp Clin Cancer Res       Date:  2021-04-19

2.  DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy.

Authors:  Haejeong Heo; Jong-Hwan Kim; Seon-Young Kim; Mirang Kim; Hyun Jung Lim; Jeong-Hwan Kim; Miso Kim; Jaemoon Koh; Joo-Young Im; Bo-Kyung Kim; Misun Won; Ji-Hwan Park; Yang-Ji Shin; Mi Ran Yun; Byoung Chul Cho; Yong Sung Kim
Journal:  Exp Mol Med       Date:  2022-08-23       Impact factor: 12.153
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.